Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.

@article{Metinta1999CisplatinMA,
  title={Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.},
  author={Muzaffer Metintaş and Necmi Ozdemir and Irfan Uçgun and Osman Elbek and Mustafa Kolsuz and Savaş Mutlu and Selma Metintaş},
  journal={Chest},
  year={1999},
  volume={116 2},
  pages={391-8}
}
STUDY OBJECTIVE To investigate the therapeutic activity and toxicity of combination chemoimmunotherapy with cisplatin, mitomycin, and interferon (IFN)-alpha2a, by comparing the responses in a group of patients with diffuse malignant pleural mesothelioma (DMPM) to the responses in a control group of DMPM patients given supportive care alone. DESIGN Patients with histopathologically confirmed DMPM were evaluated for treatment with chemoimmunotherapy. SETTING After the initial evaluation, all… CONTINUE READING